# Kartos Therapeutics

**Canonical:** https://apis.io/providers/kartos-therapeutics/  
**Website:** https://kartosthera.com/  
**APIs profiled:** 7

Kartos Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered at 275 Shoreline Drive, Redwood City, California, developing navtemadlin (KRT-232), an orally administered, potent and selective small-molecule inhibitor of MDM2. The company was founded in 2016 by Wayne Rothbaum, president of Quogue Capital and co-founder of Acerta Pharma, around an MDM2 inhibitor in-licensed from Amgen. Navtemadlin blocks the MDM2 protein that suppresses p53, restoring p53 function in tumours that retain wild-type TP53 and driving cell-cycle arrest through p21 and apoptosis through pro-apoptotic Bcl-2 family proteins. The clinical programme is centred on myelofibrosis and includes the enrolling global Phase 3 POIESIS trial of navtemadlin added to ruxolitinib (NCT06479135), the Phase 1b/2 KRT-232-109 combination study (NCT04485260), and the completed Phase 3 BOREAS study of navtemadlin versus best available therapy in JAK-inhibitor relapsed or refractory myelofibrosis (NCT03662126), with reported activity also in acute myeloid leukaemia and Merkel cell carcinoma. Kartos is led by CEO Jesse McGreivy, MD, with Srdan Verstovsek, MD, PhD as chief medical officer, and is backed by Quogue Capital, OrbiMed Advisors, Amgen, SR One, Fidelity, BlackRock, T. Rowe Price, Invus and Soleus Capital. Kartos Therapeutics runs no developer program and publishes no product API, no developer portal and no API documentation; the only machine-readable surface reachable without credentials is the WordPress REST content API behind kartosthera.com, catalogued here.

## Kin Score — 19.7 / 100 (emerging)

Scored 2026-08-12 under rubric 0.11.0. Trend: flat (+0.0 from 19.7).

| Facet | Score |
|---|---|
| Discoverability | 81.5 |
| Contract Quality | 14.4 |
| Governance | 11.5 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 16.8 |
| Commercial Clarity | 10.5 |

Regulatory layer — **Health**: 26.3 (matched via tags).

## Agent readiness — 33.1 (agent-aware)

| Dimension | Value |
|---|---|
| Spec Presence | yes |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | yes |
| Idempotency | no |
| Error Semantics | documented |
| OpenAPI Examples | partial |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | derived |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## APIs (7)

- **Kartos Therapeutics Content API** — Published pages and the site-wide search index.
- **Kartos Therapeutics Discovery API** — The route index and namespace descriptors the site publishes about itself.
- **Kartos Therapeutics Media API** — The media library — scientific figures, investor logos and presentation PDFs.
- **Kartos Therapeutics Oembed API** — The oEmbed 1.0 provider endpoint for kartosthera.com URLs.
- **Kartos Therapeutics People API** — The leadership, board and advisor team custom post type.
- **Kartos Therapeutics Science API** — The navtemadlin congress presentations and publications custom post type.
- **Kartos Therapeutics Taxonomy API** — Registered post types, statuses, taxonomies and terms.

## Security (2)

- **Kartos Therapeutics Authentication** — http · 1 scheme
- **Kartos Therapeutics Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

Company, biotechnology, pharmaceuticals, oncology, hematology, rare-disease, precision-medicine, clinical-trials, life-sciences, content-api

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/kartos-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.